The efficacy of the switch was evaluated by the reduction in the exacerbation rate and OCS intake; the improvement in lung function parameters, which was estimated from the forced expiratory volume per second (FEV1); a decrease in T2 inflammation biomarkers (e.g., eosinophils, IgE, and FeNO); and an improvement in asthma control, as measured by the asthma control test (ACT). Here, IGHE is linked to asthma.